Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

Journal of Clinical Oncology

Volumn 17, Issue 9, 1999, Pages 2859-2867

  Pyrhönen, Seppo ^a   Salminen, Eeva ^a   Ruutu, Mirja ^a   Lehtonen, Timo ^a   Nurmi, Martti ^a   Tammela, Teuvo ^a   Juusela, Harri ^a   Rintala, Erkki ^a   Hietanen, Päivi ^a   Kellokumpu Lehtinen, Pirko Liisa ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; RECOMBINANT ALPHA2A INTERFERON; VINBLASTINE; VINBLASTINE SULFATE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 2442737061     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.9.2859     Document Type: Article

References (41)

1. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 335:865-875, 1996
2. Ritchie AWS, Oliver PTD: Tumors of the kidney (other than nephroblastoma), in Peckham M, Pinedo H, Veronesi U (eds): Oxford Textbook of Oncology. Oxford, England, Oxford University Press, 1995, pp 1480-1498
3. Tomatis L: Cancer: Causes, Occurrence, and Control. Lyon, France, International Agency for Research on Cancer, 1990, p 320. IARC Scientific Publications, No. 100
4. Meyers MH, Gloeckler LA: Cancer patient survival rates: SEER program results for 10 years of follow-up. CA Cancer J Clin 39:21-32, 1989
5. Harris DT: Hormonal therapy and chemotherapy of renal carcinoma. Semin Oncol 10:422-430, 1987
6. Horoszewicz JS, Murphy GP: An assessment of the current use of human interferons in therapy of urological cancers. J Urol 142:1173-1180, 1989
7. Law TM, Motzer RJ, Mazumdat M, et al: Phase III randomized trial of inteleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76:824-832, 1995
8. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907-913, 1994
9. Minasian LM, Motzer RJ, Gluck L, et al: Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368-1375, 1993
10. Fosså SD, Kramar A, Droz J-P: Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 30A: 1310-1314, 1994
11. Negrier S, Escudier B, Lasset C, et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338:1272-1278, 1998
12. Aapro MS, Alberts DS, Salmon SE: Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol 10:161-166, 1983
13. Fosså SD, DeGaris ST: Further experience with recombinant interferon-alpha-2a with vinblastine in metastatic renal cell carcinoma. Int J Cancer 1:36-40, 1987 (suppl)
14. Cetto GL, Franceschi T, Turrina G, et al: Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma: Efficacy of low doses. Semin Surg Oncol 4:184-190, 1988
15. Bergerat JP, Herbrecht R, Defour P, et al: Combination of recombinant interferon-alpha-2a and vinblastine in advanced renal cell carcinoma. Cancer 62:2320-2324, 1988
16. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48:7310-7313, 1988
17. Doll R, Peto R: Epidemiology of cancer, in Weatherall DJ, Ledingham GG, Warrell DA (eds): Oxford Textbook of Medicine. Oxford, England, Oxford Medical Publications, 1987, pp 4095-4123
18. Hernberg M, Muhonen T, Pyrhönen S: Can the CD4+/CD8+ ratio predict the outcome of interferon-alfa therapy for renal cell carcinoma? Ann Oncol 8:71-77, 1997
19. Fosså S, Martinelli G, Otto U, et al: Recombinant interferon-alpha-2a with or without vinblastine in metastatic renal cell carcinoma: Results of a European multi-centre phase III study. Ann Oncol 3:301-305, 1992
20. Schornagel JH, Verweij J, ten Bokkel Huinink WW, et al: Phase II study of recombinant interferon-alpha-2a with vinblastine in advanced renal cell carcinoma. J Urol 142:253-258, 1989
21. Kellokumpu-Lehtinen P, Nordman E: Interferon and vinblastine treatment of advanced renal cell cancer: A clinical phase II study. J Biol Resp Mod 9:439-444, 1990
22. Kellokumpu-Lehtinen P, Jantunen I, Flander M, et al: Interferon and vinblastine treatment of advanced renal cell cancer. Acta Oncol 34:975-977, 1995
23. Sertoli MR, Brunetti F, Ardozzoni A, et al: Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. Am J Clin Oncol 12:43-45, 1989
24. Neidhart JA, Anderson SA, Harris JE, et al: Vinblastine fails to improve response of renal cancer to interferon alfa-n1: High response rate in patients with pulmonary metastases. J Clin Oncol 9:832-837, 1991
25. Kriegmair M, Oberneder R, Hofstetter A: Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology 45:758-762, 1995
26. Jones M, Philip T, Palmer P, et al: The impact of interleukin-2 on survival in renal cancer: A multivariate analysis. Cancer Biother 8:275-288, 1993
27. Maldazys JD, deKernion JB: Prognostic factors in metastatic renal carcinoma. J Urol 136:376-379, 1986
28. Creagan ET, Twito DI, Johnsson SL, et al: A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma. J Clin Oncol 9:2104-2109, 1991
29. Scheithauer W, Kuerer I, Kutzmits R: Phase II trial of recombinant interferon-alpha-2a in metastatic renal cell carcinoma. J Biol Regul Homeost Agents 1:81-86, 1987
30. Levens W, Rübben H, Ingenhag W: Long-term interferon treatment in metastatic renal cell carcinoma. Eur Urol 16:378-381, 1989
31. Kuzmits R, Kokoschka EM, Micksche M, et al: Phase II results with recombinant interferons: Renal cell carcinoma and malignant melanoma. Oncology 42:26-30, 1985 (suppl 1)
32. Umeda T, Niijima N: Phase II study of alpha interferon on renal cell carcinoma: Summary of three collaborative trials. Cancer 58:1231-1235, 1986
33. Quesada JR, Rios A, Swanson D, et al: Antitumor activity of recombinant derived interferon-alpha in metastatic cancer. J Clin Oncol 3:1522-1538, 1985
34. Porzolt F, Messerer D, Hartman R, et al: Treatment of advanced renal cell cancer with recombinant interferon-alpha as a single agent and in combination with medroxyprogesterone acetate: A randomized multicenter trial. J Cancer Res Clin Oncol 114:95-100, 1988
35. Bono AV Reali L, Benvenuti C, et al: Recombinant alpha interferon in metastatic renal cell carcinoma: A cooperative phase II study. Urology 38:60-63, 1991
36. Muss HB, Costanzi JJ, Leavitt R, et al: Recombinant alpha interferon in renal cell carcinoma: A randomized trial of two routes of administration. J Clin Oncol 5:286-291, 1987
37. Foon K, Doroshaw J, Bonnem E, et al: A prospective randomized trial of alpha 2b interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma. J Biol Response Mod 7:540-545, 1988
38. Kempf RA, Grunberg SM, Daniels JR, et al: Recombinant interferon-alpha-2 (Intron-A) in a phase II study of renal cell carcinoma. J Biol Resp Mod 5:27-30, 1986
39. Abratt RP, Pontin AR, Ball HS: Activity of a short course of interferon alfa for metastatic renal cell carcinoma: A phase 2 study. Cancer Immunol Immunother 37:140-141, 1993
40. Medical Research Council Renal Cancer Collaborators: Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomized controlled trial. Lancet 353:14-17, 1999
41. Hänninen EL, Kirchner H, Atzpodien J: Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients. J Urol 155:19-25, 1996